ARTICLE | Company News

Almirall, Bayer sales and marketing update

February 20, 2012 8:00 AM UTC

Almirall and Bayer partnered to co-promote Bayer's Xarelto rivaroxaban in Spain. The oral Factor Xa inhibitor is approved in Europe to prevent stroke and systemic embolism in atrial fibrillation (AF) patients; to treat deep vein thrombosis (DVT); to prevent recurrent DVT and pulmonary embolism following an acute DVT; and to prevent venous thromboembolic events in patients undergoing hip or knee replacement surgery. Terms were not disclosed. ...